June 13, 2018 / 11:15 AM / in 5 months

Flex Pharma to cut 60 percent of workforce

June 13 (Reuters) - U.S. drug developer Flex Pharma Inc said on Wednesday it plans to reduce its workforce by 60 percent, as part of a restructuring, and was ending certain ongoing mid-stage trials.

The company will now focus on developing its Amyotrophic lateral sclerosis (ALS) drug, FLX-787, the company’s lead product candidate, for dysphagia or difficulty in swallowing. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below